Allogeneic Cell Tumor Vaccination With Intratumoral and Distal Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tumor vaccination strategies are circumvented by the immune-evasive properties of tumor cells, as the natural selection pressure on the tumor is not strong enough to force cell death, limiting the effectiveness of immunotherapy.
Innovation Solution
A combination vaccination strategy involving intratumoral and extra-tumoral administration of allogeneic leukemia-derived cells, where the first composition is administered at the tumor site and the second composition is given at a site distal to the tumor, enhancing the immune response against the tumor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccination approaches (intradermal or intranodal injection) are used, then the immune response is activated, but the tumor evades immune control by altering itself to reduce expression of tumor antigens or by creating an inhibitory microenvironment
Solution Approach 1:
The patent divides the vaccination approach into two distinct components: (1) intratumoral administration of a first composition containing dendritic cells and tumor antigens directly into the tumor, and (2) extra-tumoral administration of a second composition containing dendritic cells and adjuvants at a site distal to the tumor. This segmentation allows each composition to target different aspects of the immune response and tumor microenvironment, overcoming the limitations of conventional single-site vaccination.
Solution Approach 2:
The patent applies different qualities to different locations: the intratumoral first composition is designed with specific properties (dendritic cells loaded with tumor antigens) to directly confront the tumor and its immunosuppressive microenvironment, while the extra-tumoral second composition uses adjuvants to systemically activate the immune system. Each location receives a tailored composition optimized for that specific site's characteristics.
2Ease of operation
If vaccination is administered at sites away from the tumor (intradermal or intranodal injection), then T cell activation occurs, but the natural selection pressure on the tumor is not strong enough to force cell death
Solution Approach 1:
The intratumoral administration of the first composition serves as a preliminary action that directly introduces dendritic cells and tumor antigens into the tumor microenvironment before the extra-tumoral vaccination. This preliminary intratumoral exposure primes the local immune environment and creates initial selection pressure on the tumor, which is then amplified by the subsequent systemic immune activation from the extra-tumoral vaccination.
3Device complexity
If a single vaccination approach is used, then the administration is simple, but the reduction of tumor growth is insufficient compared to combination strategy
Solution Approach 1:
The patent merges two previously separate vaccination approaches into a unified combination strategy: intratumoral vaccination (first composition) and extra-tumoral vaccination (second composition). By combining these two approaches, the patent achieves synergistic effects where the intratumoral component directly targets the tumor microenvironment while the extra-tumoral component provides systemic immune activation, resulting in superior tumor growth reduction compared to either approach alone.
Data Source
AI summary
Provided herein are methods for treating a tumor or generating an immune response against a tumor in a subject in need, including one or more intratumoral administration steps each comprising administering to the subject at a tumor site, an effective amount of a first composition, and one or more vaccination steps each comprising administering to the subject at a site distal to the tumor site, an effective amount of a second composition. The first and second composition may each comprise an allogeneic leukemia-derived cell that is useful in eliciting an immune response against the tumor.